Rhumbline Advisers Acquires Shares of 45,197 Renovaro Inc. (NASDAQ:RENB)

Rhumbline Advisers acquired a new stake in shares of Renovaro Inc. (NASDAQ:RENB) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 45,197 shares of the company’s stock, valued at approximately $79,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in RENB. SG Americas Securities LLC purchased a new position in shares of Renovaro during the first quarter valued at approximately $46,000. Tidal Investments LLC bought a new position in Renovaro during the 1st quarter valued at approximately $98,000. Bank of New York Mellon Corp purchased a new position in Renovaro during the second quarter valued at $220,000. Finally, Vanguard Group Inc. raised its holdings in Renovaro by 904.0% in the first quarter. Vanguard Group Inc. now owns 3,916,672 shares of the company’s stock worth $10,379,000 after buying an additional 3,526,565 shares during the last quarter. Hedge funds and other institutional investors own 71.41% of the company’s stock.

Renovaro Trading Down 2.0 %

Renovaro stock opened at $0.48 on Tuesday. Renovaro Inc. has a 12 month low of $0.42 and a 12 month high of $5.25. The stock has a fifty day simple moving average of $0.68 and a two-hundred day simple moving average of $1.41. The firm has a market cap of $71.29 million, a price-to-earnings ratio of -0.62 and a beta of 0.58.

Insider Activity at Renovaro

In related news, major shareholder Anderson Wittekind William sold 60,000 shares of the company’s stock in a transaction on Friday, July 5th. The stock was sold at an average price of $1.55, for a total transaction of $93,000.00. Following the completion of the sale, the insider now owns 974,275 shares in the company, valued at $1,510,126.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 167,842 shares of company stock valued at $252,921 over the last ninety days. Insiders own 21.72% of the company’s stock.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.